欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
诺华旗下的SANDOZ准备出售其美国仿制药业务
Fake news? Novartis confirms it has no plans to sell SandozBy Dan Stanton 26-Feb-2018 - Last updated on 26-Feb-2018 at 13:44 GMT
GettyImages/milindriNovartis is considering divesting non-core and negative margin products but confirms it has no plans to place Sandoz “on the auction block.”
A Reuters report​ based on “people familiar with the matter” ​said recently that Novartis is preparing to auction off its US generic oral solid dose business. This is far from the truth, a spokesperson from Sandoz told in-Pharmatechnologist. Sandoz is a $10bn global subsidiary of Swiss Pharma giant Novartis, and is itself made up of a number of business units. Therefore the idea that Novartis is looking to auction off Sandoz (and for as little as $1.6bn as some media reports stated) is false, we were told. However, the US generics business – which falls under the Sandoz brand – could be sold off, it was confirmed, as part of a strategy previously announced by Novartis. While the firm was unable to comment directly on any sales speculation, it told us it is following a strategy to reshape its US business towards a more specialised and differentiated portfolio. “As part of this ongoing process we are also looking at potentially divesting or discontinuing certain non-core or negative margin products.”​ The statement is in line with what management said in its end-of-year financial call last month (transcript here​): “Our energy is focused primarily of looking at the US oral solids business where it is a discrete business, it's a unique situation. There are significant pricing declines. At least in the medium term, we don't see a shift to that situation. So we are assessing how best to optimise that given that dynamic.”​
Copyright - Unless otherwise stated all contents of this web site are © 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
|